Form 4: Corcept Therapeutics Executive William Guyer Sells Shares to Cover Tax Obligations

William Guyer, Chief Development Officer at Corcept Therapeutics, sold 309 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• William Guyer, the Chief Development Officer of Corcept Therapeutics, sold 309 shares of the company's common stock on December 2, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a price of $57.68 per share.
• Following the transaction, Mr. Guyer directly owns 5,487 shares of Corcept Therapeutics stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. It is not indicative of any positive or negative sentiment towards the company's performance or future prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Similar transactions are common across the pharmaceutical and biotech industries where stock-based compensation is a significant part of executive pay.
• Many companies use restricted stock units as part of their compensation packages, and executives often sell a portion of their shares upon vesting to cover taxes.
• This type of transaction is not unusual and is generally considered a normal part of executive compensation management.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Corcept Therapeutics, William Guyer, stock sale, insider trading, tax obligations, restricted stock units, CORT